Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
A daily polypill was estimated to be cost-effective for primary CVD prevention among U.S. adults living in historically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback